This ones a heck of a specualive investment but it seems that the institutions are willing to stomp up the cash to back it in the long term.

Heres the latest news from Killik stocbrokers on the company..........

MEDICAL MARKETING Joint Venture

We recently highlighted Medical Marketing (MMG) as worthy of attention. The company, in which I have a personal share holding, has this morning announced the formation of a joint venture, Genvax, to develop a novel DNA vaccine platform technology.

Human trials have been underway since 2001 in areas such as Lymphoma and Myeloma but the technology has broad applications in cancer, viral and bacterial infections (hence the term platform). The technology works on boosting the immune system by teaching it to identify hard to recognise cancer proteins as foreign and destroy them. Early results from the 25 patient trial in lymphoma are encouraging and evaluation of the result is expected by March 2005. Successful results should mean big pharmaceutical groups will start to take financial and commercial interests around that time.

This looks to be the first of a series of announcements due from Medical Marketing as it has a range of predominantly cancer trials moving into the clinical stage. (news flow could push the price higher)

The stock has made good progress in recent sessions up to the mid-80p level where the company is valued at just under 40 million. ENDS.

Please DYOR

cheers GF.

EK has shown that he is willing and able to bend any stockmarket rules, he should be banned from all kinds of dealings

Cheers,
PM

Medical Marketing Int'l Group PLC
29 September 2005


IMMEDIATE RELEASE 29 SEPTEMBER 2005

MEDICAL MARKETING INTERNATIONAL GROUP PLC

PRELIMINARY RESULTS ANNOUNCEMENT
For the year ended 31 March 2005

Medical Marketing International Group plc ('MMI' or the 'Company'), (AIM:MMG),
the Cambridge, UK-based pharmaceutical company focused on the development of
therapies for cancer and infectious diseases is pleased to announced its
preliminary results for the year ended 31 March 2005.

HIGHLIGHTS: PIPELINE

Genvax
Lymphoma vaccine clinical trial success
Promising interim results with myeloma clinical trials
Encouraging interim results with prostate cancer trial

USA/EU patents granted

Oncosense
Preclinical data show ruthenium more effective and safer than market
leading cancer therapies
USA/EU patents granted
Lead clinical trial candidates identified
Ruthenium inventor elected to Royal Society


Viratis

Existing AIDS ribozyme technology applied to hepatitis
Rheumatoid arthritis and asthma technologies added to portfolio
Further patents granted.

HIGHLIGHTS: FINANCIAL

Operating loss down 17% (2004 included 589,710 CellFactors write-down)
Turnover maintained at 2004 levels
Planned progress of technologies reflected in increased expenditure:

o New staff recruited
o Underlying administrative expenses, which includes staff costs and
associated overheads of our scientists, up 11%
o Combined research and development and patent costs expenditure up 31%

Cash at bank up 49%
10 million institutional placing: Announced Today (please see separate
release)


Commenting on results, David Best, Executive Chairman, said:

'The significant progress made during the year would not have been possible
without the support of two important groups of people. Firstly, I thank the team
of hard-working professionals in MMI who know that they are not only enhancing
shareholder value but are also intent on making an impact on the treatment of
serious diseases. Secondly, and most importantly, we all recognise that our
progress is dependent on the continuing support of existing shareholders and the
additional support from new ones. On behalf of the whole MMI team, I thank all
shareholders and I look forward with them to seeing the full potential of MMI
being realised as we stand poised on the edge of a new era for the Company.'

For further information, please contact:

David Best, Executive Chairman
MMI Tel: +44 (0)1223 477677

Lisa Baderoon Mobile: 0772 141 3496
Rebecca Skye Dietrich
Buchanan Communications Tel: +44 (0)20 7466 5000

EXECUTIVE CHAIRMAN'S REPORT

Significant and exciting progress towards our objectives
As your board we recognise that it is our duty to create shareholder value. As a
pharmaceutical development company, MMI's business model is to identify
world-class medical research that has the potential to treat unmet need in major
therapeutic markets, markets such as cancer and infection. Developing those
technologies to the human proof-of-principle stage and ultimately licensing them
to major pharmaceutical marketing partners.

Last year, I said in my report, 'The prospects for the coming year are the most
exciting in the Company's history'. We have not been disappointed and I am
delighted to report that during the past year our portfolio of therapeutic
products continued both to grow and to progress towards and through the clinic,
adding significant value for shareholders and attracting global pharmaceutical
company interest.

Strong and progressive pipeline development
We reported the first clinical trial results for our Genvax lymphoma vaccine and
other Genvax clinical trials for myeloma and prostate cancer are underway and
progressing well. We showed in laboratory tests that our Oncosense portfolio of
ruthenium anti-cancer drugs is more effective and safer than the market-leading
drugs based on platinum. We demonstrated that the Viratis novel anti-viral
ribozymes appear to be effective against hepatitis as well as AIDS and we added
to the Viratis portfolio in the fields of rheumatoid arthritis and asthma. In
addition to technical and clinical progress, we also saw six further patents
being granted during the year.

Taken together, all these successes mean that we have a strong and competitive
pipeline of therapeutics, several of which have the potential to be blockbuster
drugs. We also expanded our relationships with academia, thus providing an
enhanced ability to secure more exciting technologies. These facts have been
recognised by a number of potential marketing partners, including a number of
the world's top pharmaceutical companies.

Heightened market interest
Investors, both institutional and private, also began to recognise the value in
MMI's pipeline. Between 31st March 2004 and 31st March 2005 the share price grew
by 287%, outperforming both the AIM (26% increase) and pharmaceutical (0%
change) benchmarks. During the same period, the value of your company grew from
29 million to 120 million. Measured against our objectives, I am satisfied
that we had a good year. Nevertheless, there is still a considerable way to go
until the significant potential of the Company is realised. Further clinical
trials and licensing agreements should have an impact on this valuation.

Funding the development
The planned progress with our pharmaceutical pipeline meant that research and
development costs increased by 31% over the previous year and patent costs rose
by 414%. In addition to these largely external costs, these developments placed
a considerable extra workload on the MMI team, which was increased in size,
resulting overall in an increase in underlying administrative expenses of 11%.
During the year we took back sub-let space in our Bioscience Innovation Centre
and fitted out three additional laboratories that were required primarily to
carry out the development work on the ruthenium and pineapple protease cancer
therapies. These plans, which were announced in the previous year, led to an
expected reduction in rental income of 65%. However, by allowing other companies
to use surplus capacity in our laboratories under our LabHotel trademark, we
were able to generate income to help offset these costs and we were also able to
contract with six global-leading equipment suppliers who have provided us with
their latest ranges that we can use free of charge for our own developments and
which we can allow other companies to use on a fee basis. Tek-check our
technology audit product for academic institutions also provided us with income
as well as being a source of new technologies for our portfolio. Genvax, for
example, was a direct result of our technology audit work for the National Blood
Service.

Although the main focus and value-driver of MMI is the development of our
pharmaceutical pipeline, fee income from LabHotel and our due diligence service
Tek-check, together increased by 49% and, as well as being strategically
relevant, helped to maintain the low cost of our business model. There was no
Tek-check due diligence income from the BioScience VCT in the second half of
this year, and the outcome of recent changes to the board of the Fund may have
an impact on future due diligence workload. We are monitoring this situation
closely. Overall, turnover remained at 2004 levels.

Operating losses for the year are down by 17%. The loss in the previous year
took into account the 589,710 impairment of our CellFactors investment, in
which MMI had a 17% stake, after that company was placed in administration. The
administrators have now liquidated CellFactors, but after their costs, it is
unlikely that there will be a significant distribution to shareholders. We have
learnt from the CellFactors lesson and MMI now funds the activities of all its
subsidiaries. This enables us to increase our equity stake, and maintain a much
greater level of control over the activities of these subsidiaries than was
possible with CellFactors.

With the continuing support of our major institutional shareholders, we ended
the year with a 49% increase in cash reserves and remained debt-free. Following
the year end I am pleased to report that existing and new institutional
shareholders have indicated their willingness to support our ambitious
development programme. Details of this will be announced separately.

Cancer and HIV - unmet need on a global scale
Although there has been much scientific progress in recent years, cancer remains
the most common form of premature death in the western world, affecting one in
three, and killing one in four. Worldwide, over 40 million people are now
infected with AIDS and there are some 300 million chronic sufferers from
hepatitis B. There is clearly much more to be done and during the coming year we
expect to see more of our cancer therapies enter or complete clinical trials.
The results of these trials may influence both pharmaceutical company interest
and the valuation of the Company. We also hope to be able to make further
progress across other aspects of the portfolio with our potential therapies,
especially those for AIDS and hepatitis in the near term and with those for
rheumatoid arthritis, asthma and drug-resistant infections in the medium-term.

A strengthening board and shareholder base
In anticipation of MMI becoming a much more valuable player in the
pharmaceutical sector, we significantly increased the number of presentations of
the MMI story to financial institutions and this led to a strengthening of our
shareholder base. We also took steps to strengthen the board of directors and Dr
James Brenton (41), a consultant cancer specialist and Cancer Research UK Senior
Clinical Research Fellow was appointed Medical Advisor and is due to join the
board as part-time Medical Director at the AGM. James is highly experienced in
running clinical trials with platinum-based cancer therapies and his expertise
will be invaluable with our ruthenium clinical trials. Rob Sprawson (35) will
also join the board at the AGM as full-time Group Finance Director replacing
John Hustler (59) who has been part time Finance Director since 2000. In
addition to his accountancy experience, Rob has nearly a decade of experience in
financial transactions in the technology sector and this skill will be extremely
useful in our licensing negotiations with major pharmaceutical companies. I look
forward to introducing the new board members to you at the AGM and I would like
to take this opportunity to thank John Hustler for helping to get us to where we
are now, and also to wish him well for the future.

There are two groups of people without whose support the significant progress we
made during the year would not have been possible. Firstly, I thank the team of
hard-working professionals in MMI who know that they are not only enhancing
shareholder value but are also intent on making an impact on the treatment of
serious diseases. Secondly, and most importantly, we all recognise that our
progress is dependent on the continuing support of existing shareholders and the
additional support from new ones. On behalf of the whole MMI team, I thank all
shareholders and I look forward with them to seeing the full potential of MMI
being realised as we stand poised on the edge of a new era for the Company.

David Best
EXECUTIVE CHAIRMAN

Medical Marketing Int'l Group PLC
29 September 2005


For Immediate Release 29 September 2005

MMI RAISES 10 MILLION
TO FUND CLINICAL TRIAL PROGRAMME

Medical Marketing International Group plc (AIM:MMG), the Cambridge, UK-based
pharmaceutical development company today announces that it has raised 10.0
million (gross) to fund the clinical trials and manufacturing programmes
primarily for its Genvax cancer vaccines and its ruthenium-based cancer
therapies.

J M Finn & Co, the Company's broker, placed 7,407,408 million new ordinary
shares with existing and new institutional shareholders at a price of 135p per
share. Application will be made for the new ordinary shares to be admitted to
AIM. When issued, the new ordinary shares will rank pari passu in all respects
with the existing ordinary shares. Following the placing, MMI will have a total
of 58,254,171 ordinary shares in issue. Dealings in the New Ordinary Shares are
expected to commence on 7 October 2005.

David Best, Chairman of MMI, commenting on this announcement said 'I am
delighted with the support we have received from existing and new institutions
during this successful placing. Importantly, we now have sufficient funds to
enable us to accelerate our ambitious clinical development programme. The new
funds will be used primarily to drive the clinical trials and manufacturing
programmes for our very promising Genvax cancer vaccines and also to complete
the commercial manufacturing of our lead ruthenium cancer therapy compounds, and
begin clinical trials. Our strengthened balance sheet will also be beneficial
whilst negotiating commercial partnerships with major pharmaceutical companies
for the market rights for these products'.



For further information, please contact:

David Best, Executive Chairman
MMI

Company valued at 120m with 58,254,171 shares issued. Sounds good to me. Patience is all that is required.

MS

Well we knew the fund raising was coming and now we have got it. Im glad they have got it out into the open. It obviously strengthens the balance sheet which is a big plus and it looks like there were no problems getting backers.

Lets now hope for some real MEATY news.

cheers GF.

Hi All,

Not far off eh :)

Just the AGM to go now ....

Cheers,
PM
==============================================
paulmasterson1 - 28 Sep 2005 11:44 - 1892 of 1900

Results out possibly this week, won't be great so expect a drop back :(

Possible placing, as no deals have been made yet, either that or deal news at the AGM in a few weeks time ....

Cheers,
PM

Spot on Paul. Keep it coming.

cheers GF.

Possible deal with a chosen manufacturer within the next few weeks for the lead RU compounds and then clinical trials thereafter is the latest plan from MMI so we should expect another 3 month delay to the early part of 2006 before entering clinical trials.
Great to see DB keeping the manufacturing in -house rather than licencing out to a big pharma at this stage.

Mitzy
Any idea who the choosen manufacture is?

MS

I've no idea mickey..I heard this info about 3 months ago but still have no idea who it can be.It shold be known in the next 3 weeks in time for the Agm..

We'll just have to wait and see then mitzy. Lets hope we see the highs of a few months back. GF are you still in? EK's still short.

MS

Thanks Paul for the Mike Walters update on MMG that you sent me,it has to be one of the most positive things i have read in a long time.
I`m sure that 2006 will be a good year for MMG
DB66

DB Hi,

I think it will be good too, but be warned about MW comments, he will ramp the price up, but only good results and deals will keep it there !

Due to the lengthy processes that MMG have to follow, I would rather the price went up on results, deals, etc, than his ramping, that way the shorters and bashers are scuppered :)

Cheers,
PM

Progress

"Medical Marketing Int'l Group PLC
07 October 2005


FOR IMMEDIATE RELEASE 7th OCTOBER 2005

MMI APPOINTS GMP MANUFACTURER FOR
RUTHENIUM CANCER THERAPIES

- In preparation for entering clinical development -

Medical Marketing International Group plc, ('MMI') the Cambridge, UK-based
pharmaceutical development company listed on the London Stock Exchange (AIM:MMG)
announces that Oncosense, MMI's wholly owned cancer therapy subsidiary, has
appointed SAFC Pharma (SAFC) to manufacture cGMP batches of the lead ruthenium
cancer therapy compounds.

SAFC, a division of Sigma-Aldrich Inc. a global leading life science and high
technology company with over 6,000 employees operating in 34 countries, has
expertise in the development and manufacturing of highly potent and cytotoxic
active pharmaceutical ingredients (HPAI). SAFC's Madison, WI (USA) site is
considered one of the premier HPAI manufacturing facilities in the world. It is
one of only a few facilities certified by SafeBridge for potent compound
handling.

Mark Burton, Technical Manager, MMI, commenting on the agreement with SAFC said:
'With SAFC we have found a manufacturer with the expertise to deliver product
rapidly. Under the agreement, Oncosense will retain ownership of all existing
and any new intellectual property that arises out of the manufacturing process.
Manufacture of the ruthenium compounds will be in the USA, our largest potential
market, at SAFC's FDA approved Madison facility. SAFC is clearly the best
manufacturer for our ruthenium compounds. They have the expertise and facilities
to produce cytotoxic pharmaceuticals to cGMP standards, enabling MMI to progress
rapidly to clinical trials whilst retaining ownership of all IP.'

Dr Michael Harris, SAFC's Director of Sales and Production, Europe said: 'We are
delighted to have been chosen by MMI to manufacture their ruthenium compounds.
In selecting SAFC for this work, MMI has recognised the abilities of our
Gillingham, UK-based process development team and the unique capabilities of our
Madison high potency cGMP facility.'

David Best, MMI's Chairman further commented: 'This agreement follows closely on
from our successful 10 million institutional placing which provides us with the
funds to accelerate our manufacturing and clinical trials programmes including
those for ruthenium and our Genvax cancer vaccines.'

It was announced yesterday 10th Otober that the Prudential have acquired a further 2,407,407 ordinary shares,taking their holding to 10,026,407 ordinary shares representing 17.21% of the companys issued share capital.
They must be quietly confident.
DB66

Back in this afternoon, 122p too good to resist, almost 10% below institutions stumping up 10million quid. 2006 should be a rewarding year for MMG holders.
Again I have a personal target and won't be afraid to sell if it goes way beyond that.

Still in and have no problems with the long term. Just holding and awaiting the Golden return.

Remember patience in most circunstances = big returns. Have you seen how many times Ive done it before.

cheers GF.

My hero.

I love you Dil, but remember Wales have no chance this year in the rugby Union. England easy.

cheers GF.

We didn't have a chance last year either :-)